Search results
Sanofi's Dupixent gets U.S. approval to treat eczema in young children
Reuters via Yahoo News· 2 years agoDupixent is now the first approved treatment for moderate-to-severe eczema in young children, Sanofi...
Treatments for Eczema
Health via Yahoo News· 6 months agoEczema (also known as dermatitis) is a condition that primarily affects the skin, causing dryness, itchiness, scaliness, rashes, and blisters. In some...
Danielle Jonas says her eczema affected her self-esteem and deterred her from going on tour often...
INSIDER via Yahoo News· 9 months agoDanielle Jonas opened up about her eczema journey in a recent interview with Insider.Courtesy of...
Sanofi's (SNY) Dupixent Gets FDA Nod for Eczema in Infants
Zacks via Yahoo Finance· 2 years agoSanofi (SNY) and partner Regeneron's label expansion application for Dupixent to include infants...
Regeneron-Sanofi's Flagship Dupixent Becomes First FDA-Approved Treatment For Prurigo Nodularis
Benzinga via Yahoo Finance· 2 years agoThe FDA approved Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA's (NASDAQ: SNY) Dupixent...
Why Tech Leader Regeneron Shouldn't Sweat Its AbbVie Rival — For Now
Investor's Business Daily· 2 years agoAbbVie could soon pressure Regeneron Pharmaceuticals in eczema treatment, an analyst said Friday as...
How to manage eczema – according to a dermatologist
The Telegraph via Yahoo News· 2 months agoThe condition can be uncomfortable and create a sense of social embarrassment among sufferers For the one in 10 adults who will develop eczema at some...
Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales
Investor's Business Daily· 5 months agoRegeneron Pharmaceuticals and Sanofi said Monday their blockbuster drug, Dupixent, significantly...
Intrinsic Eczema: Everything You Need to Know
Verywell Health via Yahoo News· 2 years agoIntrinsic eczema, a type of atopic dermatitis, is a chronic skin condition that causes itchy rashes. See pictures of intrinsic eczema and learn how to...
ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study
Zacks via Yahoo Finance· 2 months agoASLAN (ASLN) rises on upbeat initial data from a phase II study of eblasakimab in patients with...